GE blue­prints $165M bi­o­log­ics fa­cil­i­ties; Tarve­da to part­ner with Madri­gal in $163M deal

GE Health­care, which has been fo­cus­ing on reengi­neer­ing the way bi­o­log­ics are made, is in­vest­ing $165 mil­lion in four turnkey “off the shelf” fa­cil­i­ties to be man­aged by its cus­tomers in Ire­land. These new fa­cil­i­ties will cre­ate 500 new jobs.

Months af­ter chang­ing its name from Blend Ther­a­peu­tics to Tarve­da, the re­boot­ed biotech has struck a deal to col­lab­o­rate with Madri­gal Phar­ma­ceu­ti­cals on new can­cer drugs. Madri­gal is in line for up to $163 mil­lion in mile­stones. Madri­gal merged in­to Syn­ta last spring.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER